Biotech stocks will ‘outperform’ in the balance of 2022: Fahmy

A new bull market is unlikely until the U.S. Federal Reserve starts to go easy on the interest rates. Still, there are opportunities that could be rewarding in the back half of 2022. Fahmy’s bul...